KB7 Stock Overview
A healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Solventum Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$63.00 |
| 52 Week High | US$70.50 |
| 52 Week Low | US$43.00 |
| Beta | 0 |
| 11 Month Change | -4.55% |
| 3 Month Change | 16.67% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 10.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| KB7 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -6.0% | -4.9% | -1.5% |
| 1Y | n/a | -5.6% | 7.9% |
Return vs Industry: Insufficient data to determine how KB7 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how KB7 performed against the German Market.
Price Volatility
| KB7 volatility | |
|---|---|
| KB7 Average Weekly Movement | 4.9% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: KB7 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: KB7's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2023 | 22,000 | Bryan Hanson | www.solventum.com |
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.
Solventum Corporation Fundamentals Summary
| KB7 fundamental statistics | |
|---|---|
| Market cap | €11.07b |
| Earnings (TTM) | €683.93m |
| Revenue (TTM) | €7.80b |
16.1x
P/E Ratio1.4x
P/S RatioIs KB7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KB7 income statement (TTM) | |
|---|---|
| Revenue | US$8.22b |
| Cost of Revenue | US$3.58b |
| Gross Profit | US$4.63b |
| Other Expenses | US$3.91b |
| Earnings | US$720.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.17 |
| Gross Margin | 56.38% |
| Net Profit Margin | 8.76% |
| Debt/Equity Ratio | 254.0% |
How did KB7 perform over the long term?
See historical performance and comparison